Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial

IF 38.7 1区 医学 Q1 CRITICAL CARE MEDICINE
Zifeng Yang, Yangqing Zhan, Zhengtu Li, Zhengshi Lin, Zhonghao Fang, Haijun Li, Xiaolin Chen, Banghan Ding, Huiqing Zeng, Xiuwei Zhang, Yudi Song, Zejun Lin, Shiwei Liang, Jincan Luo, Jufang Huang, Xiaoxin Chen, Nanshan Zhong
{"title":"Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial","authors":"Zifeng Yang, Yangqing Zhan, Zhengtu Li, Zhengshi Lin, Zhonghao Fang, Haijun Li, Xiaolin Chen, Banghan Ding, Huiqing Zeng, Xiuwei Zhang, Yudi Song, Zejun Lin, Shiwei Liang, Jincan Luo, Jufang Huang, Xiaoxin Chen, Nanshan Zhong","doi":"10.1016/s2213-2600(25)00046-3","DOIUrl":null,"url":null,"abstract":"<h3>Background</h3>Onradivir (ZSP1273) is a potent inhibitor of the PB2 subunit of influenza A virus (IAV) polymerase. Our previous, phase 2 clinical trial showed that a 600 mg regimen of onradivir initiated within 48 h of symptom onset can expedite the recovery of adult patients from acute, uncomplicated influenza. Here, we aimed to evaluate the safety and therapeutic efficacy of onradivir in a larger group with acute, uncomplicated influenza.<h3>Methods</h3>This randomised, double-blind, multicentre, placebo-controlled and oseltamivir-controlled, phase 3 trial was conducted at 68 clinical sites in China. Eligible participants were adults (aged 18–64 years) with an influenza-like illness who screened positive by rapid IAV antigen testing at the first clinical visit, and had a fever (axillary temperature ≥38·0°C) with at least one moderate systemic and one moderate respiratory symptom within 48 h of symptom onset. Patients were randomly assigned into three treatment groups, stratified by influenza symptom scores (≤11 or ≥12), in a 2:1:1 ratio by an interactive web response system, with each treatment lasting 5 days: 600 mg oral onradivir tablets once daily, 75 mg oral oseltamivir phosphate capsules twice daily, or oral placebo. The primary outcome was the efficacy of onradivir versus placebo in the time to alleviation of symptoms (TTAS), from treatment initiation to the remission of influenza symptoms, in the intention-to-treat infection (ITTI) population (ie, all participants who were randomly assigned and tested positive for IAV). The safety endpoints were the frequency and severity of adverse events in all participants who received treatment at least once. This trial is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> (<span><span>NCT04683406</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>) and is completed. This clinical trial was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (EC-2020-080[YW]-02).<h3>Findings</h3>Between May 12, 2022, and May 16, 2023, 943 patients were screened, of whom 750 met the inclusion criteria and were randomly assigned to a group. 48 had negative IAV tests, resulting in an ITTI population of 702 participants (413 [59%] men and 289 [41%] women; mean age 28·1 years [SD 9·7]): 349 in the onradivir group, 177 in the oseltamivir group, and 176 in the placebo group. The baseline viral load (mean 5·15 log<sub>10</sub> copies per mL [SD 1·02]) and the total score of seven influenza symptoms at enrolment were similarly distributed among the groups. The median TTAS in the onradivir group was significantly shorter than that of placebo (38·83 h [95% CI 35·32–41·18] <em>vs</em> 63·35 h [55·48–68·48], difference –24·52 h, p&lt;0·0001, HR 1·53 [95% CI 1·27–1·85]) and similar to that of the oseltamivir group (42·17 h [38·27–52·83], p=0·092, HR 1·12 [0·93–1·35]. Adverse events occurred in 250 (67%) of 373 in the onradivir group, 104 (55%) of 189 in the placebo group, and 89 (47%) of 188 in the oseltamivir group. Although the incidence of diarrhoea was higher in the onradivir group (184 [49%]) than in the placebo (44 [23%]) or oseltamivir (28 [15%]) groups, most incidences were grade 1 or 2, lasted a median of 2 days (IQR 1–3), and resolved without medication.<h3>Interpretation</h3>Onradivir has similar curative efficacy to oseltamivir for acute, uncomplicated influenza infections in adult patients, with an acceptable safety profile. At a time when reduced susceptibility to antiviral drugs is a growing concern, this study indicates that onradivir could be an alternative antiviral option or a candidate for use in combination with other antiviral agents for uncomplicated IAV infection.<h3>Funding</h3>National Multidisciplinary Innovation Team Project of Traditional Chinese Medicine; National Natural Science Foundation of China; Guangdong Science and Technology Foundation; Major Project of Guangzhou National Laboratory; Guangdong Raynovent Biotechnology.","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"1 1","pages":""},"PeriodicalIF":38.7000,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2213-2600(25)00046-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Onradivir (ZSP1273) is a potent inhibitor of the PB2 subunit of influenza A virus (IAV) polymerase. Our previous, phase 2 clinical trial showed that a 600 mg regimen of onradivir initiated within 48 h of symptom onset can expedite the recovery of adult patients from acute, uncomplicated influenza. Here, we aimed to evaluate the safety and therapeutic efficacy of onradivir in a larger group with acute, uncomplicated influenza.

Methods

This randomised, double-blind, multicentre, placebo-controlled and oseltamivir-controlled, phase 3 trial was conducted at 68 clinical sites in China. Eligible participants were adults (aged 18–64 years) with an influenza-like illness who screened positive by rapid IAV antigen testing at the first clinical visit, and had a fever (axillary temperature ≥38·0°C) with at least one moderate systemic and one moderate respiratory symptom within 48 h of symptom onset. Patients were randomly assigned into three treatment groups, stratified by influenza symptom scores (≤11 or ≥12), in a 2:1:1 ratio by an interactive web response system, with each treatment lasting 5 days: 600 mg oral onradivir tablets once daily, 75 mg oral oseltamivir phosphate capsules twice daily, or oral placebo. The primary outcome was the efficacy of onradivir versus placebo in the time to alleviation of symptoms (TTAS), from treatment initiation to the remission of influenza symptoms, in the intention-to-treat infection (ITTI) population (ie, all participants who were randomly assigned and tested positive for IAV). The safety endpoints were the frequency and severity of adverse events in all participants who received treatment at least once. This trial is registered with ClinicalTrials.gov (NCT04683406) and is completed. This clinical trial was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (EC-2020-080[YW]-02).

Findings

Between May 12, 2022, and May 16, 2023, 943 patients were screened, of whom 750 met the inclusion criteria and were randomly assigned to a group. 48 had negative IAV tests, resulting in an ITTI population of 702 participants (413 [59%] men and 289 [41%] women; mean age 28·1 years [SD 9·7]): 349 in the onradivir group, 177 in the oseltamivir group, and 176 in the placebo group. The baseline viral load (mean 5·15 log10 copies per mL [SD 1·02]) and the total score of seven influenza symptoms at enrolment were similarly distributed among the groups. The median TTAS in the onradivir group was significantly shorter than that of placebo (38·83 h [95% CI 35·32–41·18] vs 63·35 h [55·48–68·48], difference –24·52 h, p<0·0001, HR 1·53 [95% CI 1·27–1·85]) and similar to that of the oseltamivir group (42·17 h [38·27–52·83], p=0·092, HR 1·12 [0·93–1·35]. Adverse events occurred in 250 (67%) of 373 in the onradivir group, 104 (55%) of 189 in the placebo group, and 89 (47%) of 188 in the oseltamivir group. Although the incidence of diarrhoea was higher in the onradivir group (184 [49%]) than in the placebo (44 [23%]) or oseltamivir (28 [15%]) groups, most incidences were grade 1 or 2, lasted a median of 2 days (IQR 1–3), and resolved without medication.

Interpretation

Onradivir has similar curative efficacy to oseltamivir for acute, uncomplicated influenza infections in adult patients, with an acceptable safety profile. At a time when reduced susceptibility to antiviral drugs is a growing concern, this study indicates that onradivir could be an alternative antiviral option or a candidate for use in combination with other antiviral agents for uncomplicated IAV infection.

Funding

National Multidisciplinary Innovation Team Project of Traditional Chinese Medicine; National Natural Science Foundation of China; Guangdong Science and Technology Foundation; Major Project of Guangzhou National Laboratory; Guangdong Raynovent Biotechnology.
中国成人急性无并发症甲型流感感染的疗效和安全性:一项多中心、双盲、随机、安慰剂对照和奥司他韦对照的3期试验
donradivir (ZSP1273)是一种有效的甲型流感病毒(IAV)聚合酶PB2亚基抑制剂。我们之前的2期临床试验表明,在症状出现48小时内开始使用600毫克的onradivir方案可以加速成人急性无并发症流感患者的康复。在这里,我们的目的是评估在一个较大的急性、无并发症流感患者组中使用onradivir的安全性和治疗效果。方法该随机、双盲、多中心、安慰剂对照和奥司他韦对照的3期临床试验在中国68个临床点进行。符合条件的受试者为患有流感样疾病的成年人(18-64岁),在首次临床就诊时通过快速IAV抗原检测筛查呈阳性,并且在症状出现48小时内发烧(腋下温度≥38.0°C),伴有至少一种中度全身症状和一种中度呼吸道症状。患者被随机分配到三个治疗组,根据流感症状评分(≤11或≥12)按2:1:1的比例通过交互式网络反应系统分层,每个治疗持续5天:600mg口服onradivir片剂每日一次,75mg口服奥司他韦磷酸胶囊每日两次,或口服安慰剂。主要结局是在意图治疗感染(ITTI)人群(即随机分配并检测出IAV阳性的所有参与者)中,从治疗开始到流感症状缓解的时间(TTAS)中,与安慰剂相比,onradivir的疗效。安全性终点是至少接受一次治疗的所有参与者不良事件的频率和严重程度。该试验已在ClinicalTrials.gov注册(NCT04683406)并已完成。本临床试验经广州医科大学第一附属医院伦理委员会批准,中国广州(EC-2020-080[YW]-02)。在2022年5月12日至2023年5月16日期间,对943名患者进行了筛查,其中750名符合纳入标准并随机分配到一组。48例IAV检测呈阴性,导致iti人群为702名参与者(男性413名[59%],女性289名[41%]);平均年龄28.1岁[SD 9.7]):奥司他韦组349岁,奥司他韦组177岁,安慰剂组176岁。入组时的基线病毒载量(平均5.15 log10拷贝/ mL [SD 1.02])和7种流感症状的总分在各组之间的分布相似。奥司他韦组的中位TTAS显著短于安慰剂组(38.83 h [95% CI 35.32 - 41.18] vs 63.35 h[55.48 - 68.48],差- 24.52 h, p= 0.0001,比差1.53 [95% CI 1.27 - 1.85]),与奥司他韦组相似(42.17 h [38.27 - 52.83], p= 0.092,比差1.12[0.93 - 1.35]。不良事件发生在373例中有250例(67%),安慰剂组有104例(55%),奥司他韦组有89例(47%)。尽管腹泻发生率在奥司他韦组(184例[49%])高于安慰剂组(44例[23%])或奥司他韦组(28例[15%]),但大多数发生率为1级或2级,持续时间中位数为2天(IQR 1 - 3),无需药物即可缓解。解释:对于成人急性、无并发症的流感感染,onradivir与oseltamivir具有相似的疗效,具有可接受的安全性。在人们越来越关注抗病毒药物敏感性降低的时候,这项研究表明,onradivir可能是一种替代抗病毒选择,或与其他抗病毒药物联合使用,用于治疗无并发症的IAV感染。国家中医药多学科创新团队项目;国家自然科学基金;广东省科学技术基金;广州国家实验室重大项目;广东瑞诺生物科技。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Lancet Respiratory Medicine
Lancet Respiratory Medicine RESPIRATORY SYSTEM-RESPIRATORY SYSTEM
CiteScore
87.10
自引率
0.70%
发文量
572
期刊介绍: The Lancet Respiratory Medicine is a renowned journal specializing in respiratory medicine and critical care. Our publication features original research that aims to advocate for change or shed light on clinical practices in the field. Additionally, we provide informative reviews on various topics related to respiratory medicine and critical care, ensuring a comprehensive coverage of the subject. The journal covers a wide range of topics including but not limited to asthma, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), tobacco control, intensive care medicine, lung cancer, cystic fibrosis, pneumonia, sarcoidosis, sepsis, mesothelioma, sleep medicine, thoracic and reconstructive surgery, tuberculosis, palliative medicine, influenza, pulmonary hypertension, pulmonary vascular disease, and respiratory infections. By encompassing such a broad spectrum of subjects, we strive to address the diverse needs and interests of our readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信